MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Mirum Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$82.24+2.10 (+2.62%)
Close on Oct 19, 2026
- Market cap
- $5.21B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
71M of 65M shares
Institutional holders
327
62 new, 43 sold out
Net institutional buying
10M
In Q2 2026
Insider trades, 12 months
1 buys · 59 sales
Net sold $33.20M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Janus Henderson Group PLC | 6,065,308 | 11.80% | 13G (passive) amendment | Dec 31, 2025 |
| JANUS HENDERSON GROUP Ltd. | 5,909,184 | 9.70% | 13G (passive) amendment | Jun 30, 2026 |
| Patrick J. Heron | 4,108,404 | 6.80% | 13D (active) amendment | Jan 23, 2026 |
| Abigail P. Johnson | 3,777,851 | 6.20% | 13G (passive) | Jun 30, 2026 |
| James N. Topper | 3,735,220 | 7.40% | 13D (active) amendment | Nov 1, 2025 |
| BlackRock, Inc. | 3,465,559 | 5.70% | 13G (passive) amendment | Mar 31, 2026 |
| Finny Kuruvilla, M.D., Ph. D. | 2,606,938 | 5.43% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MIRM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7,679,684 | 11.83% | $899.06M | – | 19.58% |
| Jupiter Topco LLC | 5,909,184 | 9.10% | $691.67M | New | 0.28% |
| BlackRock, Inc. | 4,390,063 | 6.76% | $513.94M | +543,533 | 0.01% |
| FMR LLC | 3,670,314 | 5.65% | $429.68M | +1,704,939 | 0.02% |
| Price T Rowe Associates Inc /Md/ | 2,655,607 | 4.09% | $310.89K | +938,186 | 0.03% |
| Vanguard Portfolio Management LLC | 2,377,019 | 3.66% | $278.28M | +944,936 | 0.01% |
| Vanguard Capital Management LLC | 2,254,109 | 3.47% | $263.89M | −160,667 | 0.01% |
| State Street Corp | 2,170,689 | 3.34% | $254.12M | +226,408 | 0.01% |
| William Blair Investment Management, LLC | 1,404,741 | 2.16% | $164.45M | +1,069,072 | 0.49% |
| Geode Capital Management, LLC | 1,393,908 | 2.15% | $163.21M | +133,905 | 0.01% |
| Invesco Ltd. | 1,364,084 | 2.10% | $159.69M | +1,078,848 | 0.01% |
| Wellington Management Group Llp | 1,309,987 | 2.02% | $153.36M | −24,822 | 0.03% |
| Eventide Asset Management, LLC | 1,248,389 | 1.92% | $146.20M | −160,482 | 1.95% |
| Tang Capital Management LLC | 1,236,027 | 1.90% | $144.70M | – | 6.57% |
| Capital World Investors | 1,153,480 | 1.78% | $135.04M | +429,065 | 0.02% |
| Franklin Resources Inc | 1,152,770 | 1.78% | $134.95M | +437,966 | 0.03% |
| Novo Holdings A/S | 1,125,000 | 1.73% | $131.70M | −200,000 | 7.65% |
| TCG Crossover Management, LLC | 1,062,049 | 1.64% | $124.33M | – | 2.99% |
| Bvf Inc/Il | 1,056,027 | 1.63% | $123.63M | −528,700 | 3.16% |
| Polar Capital Holdings Plc | 845,524 | 1.30% | $98.99M | +562,040 | 0.23% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 327 | 71M | 100.0% | 62 / 127 | 100 / 43 | 17M | 7M |
| Q1 2026 | 311 | 68M | 100.0% | 68 / 115 | 88 / 36 | 16M | 6M |
| Q4 2025 | 283 | 61M | 94.0% | 61 / 104 | 79 / 42 | 8M | 4M |
| Q3 2025 | 272 | 57M | 88.5% | 74 / 91 | 77 / 14 | 7M | 5M |
| Q2 2025 | 214 | 55M | 85.3% | 35 / 77 | 79 / 33 | 4M | 3M |
| Q1 2025 | 214 | 54M | 83.4% | 35 / 86 | 65 / 24 | 6M | 4M |
| Q4 2024 | 205 | 53M | 81.6% | 44 / 73 | 61 / 15 | 4M | 4M |
| Q3 2024 | 178 | 53M | 82.2% | 36 / 75 | 42 / 18 | 9M | 6M |
| Q2 2024 | 161 | 54M | 82.9% | 25 / 66 | 49 / 35 | 7M | 7M |
| Q1 2024 | 172 | 54M | 83.3% | 23 / 69 | 53 / 36 | 8M | 5M |
| Q4 2023 | 187 | 51M | 79.0% | 45 / 70 | 51 / 16 | 10M | 7M |
| Q3 2023 | 159 | 49M | 75.4% | 32 / 68 | 31 / 17 | 17M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MIRM | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,648,210 | 2.54% | $192.96M | 0.01% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,305,682 | 2.01% | $132.53M | 0.05% | May 31, 2026 |
| iShares Russell 2000 ETF | 1,218,782 | 1.88% | $142.68M | 0.17% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,189,194 | 1.83% | $139.22M | 0.07% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,123,070 | 1.73% | $131.48M | 0.14% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,059,206 | 1.63% | $124.00M | 1.16% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 823,454 | 1.27% | $96.40M | 0.66% | Jun 30, 2026 |
| Janus Henderson Triton Fund | 791,874 | 1.22% | $92.70M | 1.56% | Jun 30, 2026 |
| Eventide Gilead Fund | 709,135 | 1.09% | $83.02M | 2.41% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 686,321 | 1.06% | $80.35M | 0.17% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 563,960 | 0.87% | $59.75M | 0.68% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 558,993 | 0.86% | $65.44M | 1.13% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 551,186 | 0.85% | $64.53M | 0.07% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 530,258 | 0.82% | $62.08M | 3.47% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 518,804 | 0.80% | $54.97M | 0.16% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christopher Peetz | CHIEF EXECUTIVE OFFICER, Director | 381,940 | 0.59% | Sep 3, 2026 |
| Robert Paul Myers | Chief Medical Officer | 55 | 0.00% | Sep 22, 2026 |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 44,745 | 0.07% | Sep 15, 2026 |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 616 | 0.00% | Sep 3, 2026 |
| Peter Radovich | PRESIDENT AND COO | 57,260 | 0.09% | Jun 8, 2026 |
| Joanne Quan | CHIEF MEDICAL OFFICER | 18,864 | 0.03% | Mar 17, 2026 |
| Laura Brege | Director | 32,703 | 0.05% | Jun 17, 2026 |
| Saira Ramasastry | Director | 0 | – | Jun 17, 2026 |
| Patrick J. Heron | Director | 4,031,625 | 6.21% | Jun 17, 2026 |
| Laurent Fischer | Director | 10,727 | 0.02% | Jun 17, 2026 |
| Timothy P. Walbert | Director | 9,680 | 0.01% | Jun 17, 2026 |
| Lon Cardon | Director | 9,680 | 0.01% | Jun 17, 2026 |
| William Fairey | Director | 2,500 | 0.00% | Jun 17, 2026 |
| Michael G. Grey | Director | 330,160 | 0.51% | Jun 17, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Sep 14, 2026 | Sale | −9,943 | $98.37 | $978.09K | 44,745 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Sep 11, 2026 | Option exercise | +18,333 | – | – | 54,688 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Sep 2, 2026 | Sale(10b5-1 plan) | −658 | $100.00 | $65.80K | 616 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −21,688 | $98.91 | $2.15M | 194,440 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Sep 1, 2026 | Option exercise | +30,000 | $2.94 | $88.20K | 224,440 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −8,312 | $98.08 | $815.24K | 216,128 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Aug 18, 2026 | Option exercise | +40,000 | $6.27 | $250.80K | 41,274 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Aug 18, 2026 | Sale | −40,000 | $100.00 | $4.00M | 1,274 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Aug 11, 2026 | Sale(10b5-1 plan) | −6,001 | $99.90 | $599.50K | 36,355 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −2,300 | $100.14 | $230.32K | 194,309 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −11,683 | $98.51 | $1.15M | 202,626 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Aug 10, 2026 | Option exercise | +20,000 | $2.94 | $58.80K | 214,309 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −6,017 | $99.25 | $597.19K | 196,609 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Aug 3, 2026 | Sale(10b5-1 plan) | −1,840 | $105.29 | $193.73K | 1,274 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −3,124 | $121.67 | $380.10K | 44,057 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −1,048 | $122.43 | $128.31K | 43,009 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −528 | $123.84 | $65.39K | 42,481 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −300 | $124.94 | $37.48K | 42,181 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jul 6, 2026 | Sale(10b5-1 plan) | −1,975 | $123.74 | $244.39K | 196,019 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jul 6, 2026 | Sale(10b5-1 plan) | −1,710 | $124.79 | $213.39K | 194,309 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jul 6, 2026 | Sale(10b5-1 plan) | −4,181 | $122.34 | $511.50K | 197,994 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jul 6, 2026 | Sale(10b5-1 plan) | −12,134 | $121.65 | $1.48M | 202,175 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jul 6, 2026 | Option exercise | +20,000 | $2.94 | $58.80K | 214,309 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Jul 1, 2026 | Sale(10b5-1 plan) | −2,721 | $120.00 | $326.52K | 3,114 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Jun 17, 2026 | Sale(10b5-1 plan) | −2,594 | $101.95 | $264.46K | 5,835 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jun 9, 2026 | Option exercise | +2,393 | $26.49 | $63.39K | 47,181 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jun 8, 2026 | Sale(10b5-1 plan) | −1,567 | $95.12 | $149.05K | 44,788 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jun 8, 2026 | Sale(10b5-1 plan) | −2,258 | $92.84 | $209.63K | 47,530 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Jun 8, 2026 | Sale(10b5-1 plan) | −1,175 | $93.95 | $110.39K | 46,355 |
| Peter Radovich PRESIDENT AND COO | Jun 5, 2026 | Option exercise | +16,988 | $19.19 | $326.00K | 57,260 |
| Saira Ramasastry Director | Jun 1, 2026 | Sale(10b5-1 plan) | −3,977 | $100.00 | $397.70K | 0 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −2,602 | $94.64 | $246.25K | 221,707 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −16,595 | $95.34 | $1.58M | 205,112 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −6,926 | $96.15 | $665.93K | 198,186 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −1,973 | $97.56 | $192.49K | 196,213 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −1,021 | $98.20 | $100.26K | 195,192 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −883 | $99.66 | $88.00K | 194,309 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2026 | Option exercise | +30,000 | $2.94 | $88.20K | 224,309 |
| Saira Ramasastry Director | May 29, 2026 | Option exercise | +3,977 | – | – | 3,977 |
| Timothy P. Walbert Director | May 29, 2026 | Option exercise | +3,977 | – | – | 9,680 |
| Lon Cardon Director | May 29, 2026 | Option exercise | +3,977 | – | – | 9,680 |
| Laurent Fischer Director | May 29, 2026 | Option exercise | +3,977 | – | – | 10,727 |
| Saira Ramasastry Director | May 15, 2026 | Sale(10b5-1 plan) | −2,000 | $109.47 | $218.94K | 0 |
| Saira Ramasastry Director | May 15, 2026 | Option exercise | +2,000 | $23.51 | $47.02K | 2,000 |
| Saira Ramasastry Director | Apr 15, 2026 | Option exercise | +2,000 | $23.51 | $47.02K | 2,000 |
| Saira Ramasastry Director | Apr 15, 2026 | Sale(10b5-1 plan) | −2,000 | $96.90 | $193.80K | 0 |
| Saira Ramasastry Director | Mar 16, 2026 | Sale(10b5-1 plan) | −2,000 | $90.76 | $181.52K | 0 |
| Saira Ramasastry Director | Mar 16, 2026 | Option exercise | +2,000 | $23.51 | $47.02K | 2,000 |
| Peter Radovich PRESIDENT AND COO | Mar 16, 2026 | Sale | −16,515 | $91.98 | $1.52M | 40,272 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Mar 16, 2026 | Sale | −4,732 | $91.98 | $435.25K | 8,429 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Mar 16, 2026 | Sale | −40,985 | $91.98 | $3.77M | 194,309 |
| Joanne Quan CHIEF MEDICAL OFFICER | Mar 16, 2026 | Sale | −7,287 | $91.98 | $670.26K | 18,864 |
| Eric Bjerkholt CHIEF FINANCIAL OFFICER | Mar 16, 2026 | Sale | −7,287 | $91.98 | $670.26K | 49,788 |
| Peter Radovich PRESIDENT AND COO | Mar 15, 2026 | Option exercise | +7,220 | – | – | 33,787 |
| Peter Radovich PRESIDENT AND COO | Mar 15, 2026 | Option exercise | +23,000 | – | – | 56,787 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Mar 15, 2026 | Option exercise | +2,658 | – | – | 7,161 |
| Jolanda Howe SVP, GLOBAL CONTROLLER | Mar 15, 2026 | Option exercise | +6,000 | – | – | 13,161 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Mar 15, 2026 | Option exercise | +50,000 | – | – | 235,294 |
| Christopher Peetz CHIEF EXECUTIVE OFFICER, Director | Mar 15, 2026 | Option exercise | +25,000 | – | – | 185,294 |
| Joanne Quan CHIEF MEDICAL OFFICER | Mar 15, 2026 | Option exercise | +13,334 | – | – | 26,151 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Bjerkholt Eric Officer | Sep 15, 2026 | 9,943 | $978.09K | Sep 14, 2026 | Restricted Stock Units vesting under registered plan |
| Marie Howe Jolanda Officer | Sep 2, 2026 | 658 | $65.80K | Sep 2, 2026 | Restricted Stock |
| Peetz Christopher Officer, Director | Sep 1, 2026 | 30,000 | $2.96M | Sep 1, 2026 | Stock Option Exercise |
| Marie Howe Jolanda Officer | Aug 18, 2026 | 40,000 | $4.00M | Aug 18, 2026 | Stock Option Exercise |
| Bjerkholt Eric Officer | Aug 11, 2026 | 6,001 | $599.51K | Aug 11, 2026 | Restricted Stock |
| Peetz Christopher Officer, Director | Aug 10, 2026 | 20,000 | $1.98M | Aug 10, 2026 | Stock Option Exercise |
| Marie Howe Jolanda Officer | Aug 3, 2026 | 1,840 | $193.73K | Aug 3, 2026 | Restricted Stock |
| Bjerkholt Eric Officer | Jul 6, 2026 | 5,000 | $611.27K | Jul 6, 2026 | Restricted Stock |
| Peetz Christopher Officer, Director | Jul 6, 2026 | 20,000 | $2.45M | Jul 6, 2026 | Stock Option Exercise |
| Marie Howe Jolanda Officer | Jul 1, 2026 | 2,721 | $326.52K | Jul 1, 2026 | Performance Shares |
| Marie Howe Jolanda Officer | Jun 17, 2026 | 2,594 | $264.46K | Jun 17, 2026 | Performance Shares |
| Bjerkholt Eric Officer | Jun 8, 2026 | 5,000 | $469.07K | Jun 8, 2026 | Restricted Stock |
| Ramasastry Saira Director | Jun 1, 2026 | 3,977 | $397.70K | Jun 1, 2026 | Restricted Stock |
| Peetz Christopher Officer, Director | Jun 1, 2026 | 30,000 | $2.88M | Jun 1, 2026 | Stock Option Exercise |
| Ramasastry Saira Director | May 15, 2026 | 2,000 | $218.94K | May 15, 2026 | Stock Option Exercise |